Srs Capital Advisors, Inc. Biotechnology

Srs Capital Advisors, Inc.

$1.5 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
LRMR Larimar Therapeutics, Inc.	$102M	$1,000 0.0% of portfolio	405	Q4 2024 Added 41.61%
IBRX Immunity Bio, Inc.	$1.26B	$1,000 0.0% of portfolio	600	Q4 2024 Reduced 1.32%
AXSM Axsome Therapeutics, Inc.	$5.08B	$1,000 0.0% of portfolio	18	Q4 2024 Added 63.64%
RCKT Rocket Pharmaceuticals, Inc.	$574M	$1,000 0.0% of portfolio	120	Q4 2024 New
RVNC Revance Therapeutics, Inc.	$212M	$1,000 0.0% of portfolio	476	Q4 2024 Added 127.75%
RVMD Revolution Medicines, Inc.	$3.28B	$1,000 0.0% of portfolio	31	Q2 2024 New
ENLV Enlivex Therapeutics Ltd.	$18.8M	$1,000 0.0% of portfolio	1,015	Q4 2024 Added 65.04%
GLPG Galapagos Nv	$1.68B	$1,000 0.0% of portfolio	40	Q3 2024 New
LQDA Liquidia Corp	$971M	$1,000 0.0% of portfolio	92	Q4 2024 Reduced 15.6%
ACLX Arcellx, Inc.	$2.98B	$1,000 0.0% of portfolio	14	Q4 2024 New
ERAS Erasca, Inc.	$186M	$1,000 0.0% of portfolio	424	Q4 2024 Reduced 49.88%
ROIV Roivant Sciences Ltd.	$7.31B	$1,000 0.0% of portfolio	88	Q3 2024 New
ALDX Aldeyra Therapeutics, Inc.	$389M	$0 0.0% of portfolio	182	Q4 2024 Reduced 31.58%
INSM Insmed Inc	$10.6B	$0 0.0% of portfolio	13	Q4 2024 Reduced 51.85%
DSGN Design Therapeutics, Inc.	$235M	$0 0.0% of portfolio	143	Q4 2024 Reduced 41.39%
AURA Aura Biosciences, Inc.	$186M	$0 0.0% of portfolio	102	Q4 2024 Added 108.16%
ACAD Acadia Pharmaceuticals Inc	$2.76B	$0 0.0% of portfolio	45	Q4 2024 Added 2.27%
PTGX Protagonist Therapeutics, Inc	$2.4B	$0 0.0% of portfolio	21	Q4 2024 New
BEAM Beam Therapeutics Inc.	$1.56B	$0 0.0% of portfolio	30	Q4 2024 New
OMER Omeros Corp	$531M	$0 0.0% of portfolio	75	Q4 2024 Reduced 58.33%
BGNE Bei Gene, Ltd.	$23.5B	$0 0.0% of portfolio	4	Q3 2024 Reduced 42.86%
KMPH Kempharm, Inc	$170M	$0 0.0% of portfolio	87	Q2 2024 New
MGTX Meira G Tx Holdings PLC	$330M	$0 0.0% of portfolio	113	Q4 2024 Added 54.79%
ANNX Annexon, Inc.	$109M	$0 0.0% of portfolio	133	Q4 2024 Reduced 70.9%
VCYT Veracyte, Inc.	$2.16B	$0 0.0% of portfolio	17	Q4 2024 Reduced 10.53%
ETNB 89bio, Inc.	$376M	$0 0.0% of portfolio	84	Q4 2024 Added 154.55%
ARVN Arvinas, Inc.	$404M	$0 0.0% of portfolio	34	Q4 2024 New
NUVB Nuvation Bio Inc.	$395M	$0 0.0% of portfolio	234	Q2 2024 New
AKRO Akero Therapeutics, Inc.	$1.98B	$0 0.0% of portfolio	22	Q4 2024 New
PLRX Pliant Therapeutics, Inc.	$71.6M	$0 0.0% of portfolio	46	Q4 2024 New
TGTX Tg Therapeutics, Inc.	$5.79B	$0 0.0% of portfolio	20	Q4 2024 New
ARDX Ardelyx, Inc.	$762M	$0 0.0% of portfolio	118	Q4 2024 New
ATXS Astria Therapeutics, Inc.	$86.5M	$0 0.0% of portfolio	65	Q4 2024 New
TERN Terns Pharmaceuticals, Inc.	$110M	$0 0.0% of portfolio	103	Q4 2024 New
VKTX Viking Therapeutics, Inc.	$1.97B	$0 0.0% of portfolio	14	Q4 2024 Added 180.0%
ORIC Oric Pharmaceuticals, Inc.	$249M	$0 0.0% of portfolio	68	Q4 2024 New
HALO Halozyme Therapeutics, Inc.	$8.89B	$0 0.0% of portfolio	11	Q4 2024 Reduced 62.07%
IKNA Ikena Oncology, Inc.	$47.9M	$0 0.0% of portfolio	235	Q4 2024 Reduced 21.4%
OLMA Olema Pharmaceuticals, Inc.	$171M	$0 0.0% of portfolio	65	Q4 2024 New
ARQT Arcutis Biotherapeutics, Inc.	$947M	$0 0.0% of portfolio	26	Q4 2024 Reduced 96.51%
AVTE Aerovate Therapeutics, Inc.	$61.9M	$0 0.0% of portfolio	117	Q2 2024 New
CRNX Crinetics Pharmaceuticals, Inc.	$1.87B	$0 0.0% of portfolio	6	Q4 2024 New
FOLD Amicus Therapeutics, Inc.	$2.36B	$0 0.0% of portfolio	26	Q4 2024 Reduced 72.34%
PLX Protalix Bio Therapeutics, Inc.	$128M	$0 0.0% of portfolio	39	Q2 2024 New
VNDA Vanda Pharmaceuticals Inc.	$265M	$0 0.0% of portfolio	9	Q4 2024 Reduced 99.53%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.